At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Vinflunine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Vinflunine and Trastuzumab for Breast Neoplasms and Breast Cancer. Completed, enrolled 32 participants across 10 sites.
Detailed Summary
This research study involves the anti-cancer medication trastuzumab and the investigational drug vinflunine. The purpose of this trials is to see if trastuzumab and vinflunine used in combination or vinflunine alone is effective in the treatment of metastatic breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms, Breast Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
First PostedJan 2006
Primary CompletionFeb 2008
Study CompletionNov 2010
TodayJul 2026
First PostedJan 31, 2006
Enrollment StartJan 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.4 years ago
Interventions
Vinfluninedrug
Novel second generation vinca alkaloid
Trastuzumabdrug
Anti-HER2 monoclonal antibody